Guangzhou Baiyunshan Hanfang Launches Injectable Medium Chain Triglycerides

Homegrown Supplier Delivers Stable, Globally Compliant Solution to Address Pharmaceutical Supply Chain Gaps

Guangzhou, China – 2026 – Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd., a leading provider of high-end pharmaceutical lipid excipients and APIs, today officially launches its injectable medium chain triglycerides (MCTs) for global pharmaceutical and nutraceutical manufacturers. This domestically developed product addresses the core pain point of unstable supply for injectable-grade excipients, which were previously dominated by foreign suppliers. With key advantages including domestic substitution, global regulatory compliance, and reliable mass production capacity, the launch aims to strengthen the company’s global footprint in the high-end pharmaceutical excipient market. The product is now available for pre-order worldwide through the official website and authorized distributors.

Core Technical Breakthroughs and Product Advantages

1. Domestic Substitution for Global Supply Chain Security: The injectable MCTs break long-term foreign monopolies in high-end pharmaceutical lipid excipients, increasing the localization rate of such products from 10% to 90%. This provides a stable, reliable alternative for global manufacturers facing supply chain disruptions.

2. Green and Efficient Manufacturing Technology: The product is produced using the company’s proprietary integrated green technology, combining supercritical CO₂ extraction, membrane separation, and chromatography separation to replace traditional polluting processes. This ensures high product purity while reducing environmental impact.

3. Versatile Application Scenarios: As an API, solvent, and emulsifier, the injectable MCTs caters to the needs of functional food and medical food manufacturers, as well as API procurement agents, supporting a wide range of high-end formulation development.

Global Compliance and Certifications

To meet global market access requirements, the injectable MCTs fully complies with international standards and has obtained a series of authoritative certifications, including EU CEP, US FDA US-DMF, Mexico Cofepris, and India DCGI. These certifications ensure the product meets regulatory requirements in major markets across Europe, North America, and Asia-Pacific, enabling widespread global application.

Supply and Customization Services

The injectable MCTs is now open for pre-order globally through Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd.’s official website (http://byshanhanfang.com/) and authorized distributors. In addition to standard products, the company offers customized processing services to meet the diverse needs of different industries and projects, supporting flexible formulation adjustments and personalized supply solutions.

Executive Quote

"The launch of our injectable medium chain triglycerides marks a critical step in advancing technological self-reliance for China’s biopharmaceutical industry and addressing global supply chain vulnerabilities," said Xu Wendong, General Manager and Deputy Director of the National Engineering Research Center at Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd.. "We are committed to providing stable, high-quality domestic alternatives to global partners, supporting the safe and efficient production of pharmaceuticals and health products worldwide."

Industry Context and Corporate Strategy

Against the backdrop of growing global demand for reliable, compliant pharmaceutical excipients, the reliance on imported high-end lipid products has created supply chain risks for manufacturers. Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd.’s launch of injectable MCTs fills this gap, leveraging its national-level R&D platforms and technical expertise to deliver a trusted domestic solution. This aligns with the company’s strategic focus on breaking "neck卡" technologies and ensuring the security of the pharmaceutical industry chain.

Future Plans

Looking ahead, Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd. will continue to deepen its investment in high-end pharmaceutical lipid excipient R&D, launching more innovative products tailored to global market needs. The company will also expand its global sales and service network, providing localized technical support to clients in more countries and regions.

Company Profile

Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd. was founded in 1998 and is a state-controlled core enterprise under the Guangzhou Pharmaceutical Holdings (GPHL) Group. As a national-level specialized, sophisticated, unique, and new "Little Giant" enterprise, it operates the only national engineering research center for traditional Chinese medicine process technology and new drug development. The company’s core businesses include APIs, pharmaceutical lipid excipients, health products, and technical services, with products sold in over 20 countries and regions and serving more than 1,000 clients, including B. Braun Company and AstraZeneca. Its mission is to achieve technological self-reliance, solve "neck卡" technical problems, and ensure the security of the pharmaceutical industry chain.

For more information, visit http://byshanhanfang.com/

Contact Information

Company: Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd.
Official Website: http://byshanhanfang.com/

© 2026 Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd. All rights reserved.